Clinical Trial Update: Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the analgesic efficacy and safety of T-62 in postherpetic neuralgia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• T-62

Snippet

Sponsor: Pfizer | Conditions: Postherpetic Neuralgia | Phase 2 | Status: TERMINATED